131450-41-4

Upstream product

• 3392-11-8 2,5-dioxopyrrolidin-1-yl N-(tert-butoxycarbonyl)-L-tryptophanate 
• 131450-40-3 H-Lys(CBz)-Asp(OBn)-Phe-NH₂ hydrochloride 
• 2389-45-9 Boc-Lys(Z)-OH 
• 65864-23-5 L-α-aspartyl-(L)-phenylalaninamide phenylmethyl ester mono(hydrochloride) 
• 131450-39-0 Boc-Lys(Cbz)-Asp(OBzl)-Phe-NH₂ 
• 60058-69-7 (tert-butyloxycarbonyl)-β-benzyl-L-aspartyl-L-phenylalanine amide 
• 65864-22-4 (S)-2-amino-3-phenylpropionamide hydrochloride 
• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 

Downstream Products

• 27168-83-8 Boc-Trp-Lys-Asp-Phe-NH₂ 
• 131450-42-5 Boc-Trp-Lys-Asp-Phe-NH₂ acetic acid salt 
• 130408-70-7 (S)-3-[(S)-2-[(S)-2-tert-Butoxycarbonylamino-3-(1H-indol-3-yl)-propionylamino]-6-(3-o-tolyl-ureido)-hexanoylamino]-N-((S)-1-carbamoyl-2-phenyl-ethyl)-succinamic acid 
• 130408-72-9 (S)-3-[(S)-2-[(S)-2-tert-Butoxycarbonylamino-3-(1H-indol-3-yl)-propionylamino]-6-(3-m-tolyl-ureido)-hexanoylamino]-N-((S)-1-carbamoyl-2-phenyl-ethyl)-succinamic acid 
• 130408-73-0 (S)-3-[(S)-2-[(S)-2-tert-Butoxycarbonylamino-3-(1H-indol-3-yl)-propionylamino]-6-(3-p-tolyl-ureido)-hexanoylamino]-N-((S)-1-carbamoyl-2-phenyl-ethyl)-succinamic acid 
• 130408-76-3 (S)-3-{(S)-2-[(S)-2-tert-Butoxycarbonylamino-3-(1H-indol-3-yl)-propionylamino]-6-[3-(2-methoxy-phenyl)-ureido]-hexanoylamino}-N-((S)-1-carbamoyl-2-phenyl-ethyl)-succinamic acid 
• 131449-86-0 (S)-3-{(S)-2-[(S)-2-tert-Butoxycarbonylamino-3-(1H-indol-3-yl)-propionylamino]-6-[3-(2-nitro-phenyl)-ureido]-hexanoylamino}-N-((S)-1-carbamoyl-2-phenyl-ethyl)-succinamic acid 

Relevant academic research and scientific papers

Minor structural differences in Boc-CCK-4 derivatives dictate affinity and selectivity for CCK-A and CCK-B reeeptors

We previously reported novel Boc-CCK-4 (Boc-Trp-Met-Asp-Phe-NH2) derivatives possessing the general structure Boc-Trp-Lys[Nε-CO-NH-(R-Ph)]- Asp-Phe-NH2 (Shiosaki et al. J. Med. Chem. 1991, 34, 2837-2842). In contrast to Boc-CCK-4, wh

Boc-CCK-4 derivatives containing side-chain ureas as potent and selective CCK-A receptor agonists

Novel Boc-CCK-4 derivatives were communicated recently as having high potency and selectivity for the CCK-A receptor (Shiosaki et al. J. Med. Chem. 1990, 33, 2950-2952). While Boc-CCK-4 binds selectively to the CCK-B receptor, replacement of the methionin